| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Transfusion | 13 | 2024 | 296 | 2.220 |
Why?
|
| Anticoagulants | 11 | 2024 | 628 | 1.620 |
Why?
|
| Cardiac Surgical Procedures | 9 | 2024 | 1162 | 1.260 |
Why?
|
| Blood Preservation | 4 | 2021 | 30 | 1.100 |
Why?
|
| Blood Loss, Surgical | 4 | 2024 | 158 | 1.060 |
Why?
|
| Heparin | 7 | 2024 | 229 | 1.040 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2015 | 292 | 0.950 |
Why?
|
| Blood Platelets | 4 | 2024 | 335 | 0.910 |
Why?
|
| Postoperative Hemorrhage | 6 | 2024 | 82 | 0.910 |
Why?
|
| Perioperative Care | 3 | 2023 | 212 | 0.870 |
Why?
|
| Rivers | 1 | 2023 | 16 | 0.810 |
Why?
|
| Heart-Assist Devices | 9 | 2023 | 1099 | 0.750 |
Why?
|
| Thrombocytopenia | 4 | 2019 | 235 | 0.690 |
Why?
|
| Blood Coagulation | 5 | 2018 | 134 | 0.680 |
Why?
|
| Factor VIII | 2 | 2017 | 48 | 0.640 |
Why?
|
| Immunoassay | 1 | 2019 | 137 | 0.610 |
Why?
|
| Bacteriological Techniques | 1 | 2019 | 88 | 0.610 |
Why?
|
| Platelet-Rich Plasma | 1 | 2019 | 18 | 0.610 |
Why?
|
| Hemodynamics | 2 | 2023 | 819 | 0.610 |
Why?
|
| Hemorrhage | 2 | 2018 | 517 | 0.560 |
Why?
|
| Fibrinogen | 3 | 2017 | 163 | 0.550 |
Why?
|
| Hemostatic Techniques | 1 | 2017 | 34 | 0.530 |
Why?
|
| Hemostatics | 1 | 2017 | 62 | 0.520 |
Why?
|
| von Willebrand Factor | 1 | 2017 | 205 | 0.490 |
Why?
|
| Jehovah's Witnesses | 1 | 2015 | 17 | 0.480 |
Why?
|
| Standard of Care | 1 | 2016 | 136 | 0.480 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 138 | 0.460 |
Why?
|
| Blood Coagulation Factors | 2 | 2012 | 35 | 0.380 |
Why?
|
| Health Care Costs | 1 | 2015 | 409 | 0.380 |
Why?
|
| Coronary Artery Bypass | 4 | 2004 | 533 | 0.330 |
Why?
|
| Fibrinolytic Agents | 1 | 2011 | 209 | 0.310 |
Why?
|
| Humans | 57 | 2024 | 133150 | 0.310 |
Why?
|
| Plasma | 3 | 2021 | 105 | 0.290 |
Why?
|
| Erythrocyte Transfusion | 4 | 2015 | 136 | 0.280 |
Why?
|
| Cardiopulmonary Bypass | 5 | 2019 | 358 | 0.270 |
Why?
|
| Platelet Function Tests | 1 | 2006 | 41 | 0.260 |
Why?
|
| Platelet Transfusion | 3 | 2021 | 54 | 0.260 |
Why?
|
| Thoracic Surgery | 1 | 2008 | 166 | 0.250 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2024 | 653 | 0.240 |
Why?
|
| Societies, Medical | 2 | 2024 | 780 | 0.230 |
Why?
|
| Hemoglobins | 5 | 2021 | 322 | 0.220 |
Why?
|
| Thrombelastography | 1 | 2024 | 59 | 0.210 |
Why?
|
| Shock, Cardiogenic | 2 | 2021 | 213 | 0.200 |
Why?
|
| Plasma Exchange | 2 | 2018 | 89 | 0.200 |
Why?
|
| Quality Indicators, Health Care | 1 | 2024 | 230 | 0.190 |
Why?
|
| Blood Transfusion, Autologous | 2 | 2019 | 35 | 0.180 |
Why?
|
| Blood Component Transfusion | 1 | 2021 | 58 | 0.180 |
Why?
|
| Monitoring, Intraoperative | 1 | 2021 | 133 | 0.170 |
Why?
|
| Platelet Factor 4 | 3 | 2016 | 23 | 0.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2013 | 1191 | 0.160 |
Why?
|
| Plasmapheresis | 1 | 2019 | 33 | 0.160 |
Why?
|
| Time Factors | 7 | 2017 | 6530 | 0.160 |
Why?
|
| Administration, Oral | 2 | 2018 | 713 | 0.160 |
Why?
|
| Thrombosis | 2 | 2019 | 543 | 0.150 |
Why?
|
| Workflow | 1 | 2019 | 135 | 0.150 |
Why?
|
| Antifibrinolytic Agents | 2 | 2011 | 41 | 0.150 |
Why?
|
| Tissue Donors | 2 | 2012 | 507 | 0.150 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 84 | 0.150 |
Why?
|
| Ticlopidine | 2 | 2011 | 30 | 0.140 |
Why?
|
| Erythropoietin | 2 | 2009 | 110 | 0.140 |
Why?
|
| Administration, Topical | 1 | 2017 | 142 | 0.130 |
Why?
|
| Hemagglutinins | 1 | 2016 | 25 | 0.130 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2016 | 27 | 0.130 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2016 | 29 | 0.130 |
Why?
|
| Vascular Access Devices | 1 | 2016 | 36 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 299 | 0.120 |
Why?
|
| Hyperthermia, Induced | 1 | 2016 | 58 | 0.120 |
Why?
|
| Embolism, Amniotic Fluid | 1 | 2016 | 31 | 0.120 |
Why?
|
| Hematologic Tests | 1 | 2015 | 37 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2018 | 13097 | 0.120 |
Why?
|
| Bacteria | 1 | 2019 | 534 | 0.120 |
Why?
|
| Factor Xa Inhibitors | 2 | 2018 | 69 | 0.120 |
Why?
|
| Preoperative Care | 2 | 2008 | 373 | 0.110 |
Why?
|
| Patient Selection | 1 | 2018 | 732 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 679 | 0.110 |
Why?
|
| Middle Aged | 18 | 2024 | 28926 | 0.110 |
Why?
|
| Anemia | 2 | 2009 | 349 | 0.110 |
Why?
|
| Aged | 13 | 2024 | 21467 | 0.110 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 2090 | 0.100 |
Why?
|
| Female | 25 | 2024 | 71375 | 0.100 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2013 | 42 | 0.100 |
Why?
|
| Antithrombins | 2 | 2011 | 61 | 0.100 |
Why?
|
| Blood Safety | 1 | 2012 | 4 | 0.100 |
Why?
|
| Factor VII | 1 | 2012 | 18 | 0.100 |
Why?
|
| Bone Marrow | 2 | 2011 | 332 | 0.100 |
Why?
|
| Freezing | 1 | 2012 | 29 | 0.100 |
Why?
|
| Factor V | 1 | 2012 | 16 | 0.100 |
Why?
|
| Personnel Selection | 1 | 2013 | 68 | 0.100 |
Why?
|
| Male | 23 | 2024 | 65455 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 2013 | 124 | 0.090 |
Why?
|
| Cryopreservation | 1 | 2012 | 73 | 0.090 |
Why?
|
| Perfusion | 1 | 2013 | 209 | 0.090 |
Why?
|
| National Health Programs | 1 | 2011 | 21 | 0.090 |
Why?
|
| Hypothermia, Induced | 1 | 2013 | 169 | 0.090 |
Why?
|
| Temperature | 1 | 2012 | 325 | 0.090 |
Why?
|
| Coagulants | 1 | 2011 | 8 | 0.090 |
Why?
|
| Hemostasis, Surgical | 1 | 2011 | 36 | 0.090 |
Why?
|
| Vitamin K | 1 | 2011 | 39 | 0.090 |
Why?
|
| Heart Failure | 4 | 2009 | 2428 | 0.090 |
Why?
|
| Transplantation | 1 | 1991 | 27 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 699 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 2296 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2013 | 614 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2016 | 552 | 0.080 |
Why?
|
| Laboratories | 1 | 1991 | 89 | 0.080 |
Why?
|
| Warfarin | 1 | 2011 | 134 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2012 | 395 | 0.080 |
Why?
|
| Aspirin | 1 | 2011 | 231 | 0.080 |
Why?
|
| Platelet Activation | 1 | 2009 | 71 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 893 | 0.080 |
Why?
|
| Cell Communication | 1 | 2009 | 190 | 0.070 |
Why?
|
| Erythrocyte Aging | 2 | 1986 | 8 | 0.070 |
Why?
|
| Aorta, Thoracic | 1 | 2013 | 542 | 0.070 |
Why?
|
| Congresses as Topic | 3 | 2016 | 191 | 0.070 |
Why?
|
| Risk Factors | 5 | 2018 | 10933 | 0.070 |
Why?
|
| Leukocytes | 1 | 2009 | 215 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2015 | 3717 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 1 | 1989 | 128 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 1 | 2013 | 562 | 0.070 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1989 | 175 | 0.070 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 503 | 0.070 |
Why?
|
| Erythrocytes | 2 | 1986 | 232 | 0.070 |
Why?
|
| Bloodletting | 3 | 1989 | 5 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 682 | 0.060 |
Why?
|
| Blood Donors | 2 | 2021 | 61 | 0.060 |
Why?
|
| Isoantibodies | 1 | 1986 | 59 | 0.060 |
Why?
|
| ABO Blood-Group System | 1 | 1986 | 65 | 0.060 |
Why?
|
| Dalteparin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Adult | 11 | 2024 | 31625 | 0.060 |
Why?
|
| Plasminogen Activators | 1 | 2005 | 21 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2006 | 191 | 0.060 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 1984 | 13 | 0.050 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 1984 | 29 | 0.050 |
Why?
|
| Thromboembolism | 1 | 2005 | 93 | 0.050 |
Why?
|
| Fetal Monitoring | 1 | 1984 | 58 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 121 | 0.050 |
Why?
|
| Cell Separation | 1 | 1984 | 231 | 0.050 |
Why?
|
| Pediatrics | 1 | 2013 | 1218 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2005 | 185 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 164 | 0.050 |
Why?
|
| Case Management | 1 | 2003 | 21 | 0.050 |
Why?
|
| Prosthesis Implantation | 1 | 2005 | 152 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1989 | 571 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2024 | 241 | 0.050 |
Why?
|
| Retrospective Studies | 7 | 2024 | 17537 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2013 | 1250 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2005 | 190 | 0.050 |
Why?
|
| Platelet Aggregation | 2 | 2009 | 120 | 0.050 |
Why?
|
| Blood Banks | 1 | 2021 | 11 | 0.050 |
Why?
|
| Length of Stay | 2 | 2015 | 1392 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 40 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 3086 | 0.040 |
Why?
|
| International Normalized Ratio | 1 | 2021 | 45 | 0.040 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 476 | 0.040 |
Why?
|
| Reoperation | 2 | 2013 | 856 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2008 | 887 | 0.040 |
Why?
|
| Consensus | 1 | 2024 | 724 | 0.040 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2021 | 61 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 1986 | 574 | 0.040 |
Why?
|
| United States | 3 | 2024 | 11721 | 0.040 |
Why?
|
| Anemia, Sickle Cell | 1 | 1984 | 345 | 0.040 |
Why?
|
| Differential Threshold | 1 | 1999 | 10 | 0.040 |
Why?
|
| Fetal Diseases | 1 | 1984 | 461 | 0.040 |
Why?
|
| Blood Coagulation Tests | 4 | 2005 | 62 | 0.040 |
Why?
|
| Logistic Models | 2 | 2015 | 1862 | 0.040 |
Why?
|
| Morbidity | 1 | 1999 | 255 | 0.040 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 1431 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 1467 | 0.040 |
Why?
|
| Health Surveys | 1 | 1999 | 259 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2008 | 39 | 0.040 |
Why?
|
| Algorithms | 2 | 2004 | 1726 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 441 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1462 | 0.030 |
Why?
|
| Rivaroxaban | 1 | 2018 | 58 | 0.030 |
Why?
|
| Inpatients | 1 | 2021 | 552 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2021 | 1464 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 3987 | 0.030 |
Why?
|
| Hirudins | 2 | 2008 | 40 | 0.030 |
Why?
|
| Stroke | 2 | 2018 | 1079 | 0.030 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2015 | 17 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2008 | 211 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 66 | 0.030 |
Why?
|
| Monitoring, Physiologic | 2 | 1991 | 379 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2015 | 197 | 0.030 |
Why?
|
| Prothrombin Time | 3 | 2008 | 38 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 597 | 0.030 |
Why?
|
| Hemodilution | 1 | 1994 | 15 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 3 | 2008 | 50 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 1995 | 126 | 0.030 |
Why?
|
| Fibrinolysis | 1 | 1994 | 44 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 899 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1995 | 807 | 0.030 |
Why?
|
| Multiple Organ Failure | 1 | 2015 | 144 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 568 | 0.030 |
Why?
|
| Mortality | 1 | 2015 | 260 | 0.030 |
Why?
|
| Pulmonary Artery | 3 | 2006 | 464 | 0.030 |
Why?
|
| Blood Coagulation Disorders | 1 | 1994 | 110 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 593 | 0.020 |
Why?
|
| Data Collection | 1 | 2013 | 395 | 0.020 |
Why?
|
| Cyclosporins | 1 | 1991 | 15 | 0.020 |
Why?
|
| Calcium | 2 | 2005 | 1103 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 718 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 1991 | 111 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1964 | 0.020 |
Why?
|
| Hypothermia | 1 | 1990 | 64 | 0.020 |
Why?
|
| Pregnancy | 3 | 2016 | 7589 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2013 | 472 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 72 | 0.020 |
Why?
|
| P-Selectin | 1 | 2009 | 74 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 88 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2009 | 5200 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 1340 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 327 | 0.020 |
Why?
|
| Blood Specimen Collection | 1 | 1989 | 48 | 0.020 |
Why?
|
| Hemostasis | 1 | 1989 | 72 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1989 | 142 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1991 | 312 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2008 | 8 | 0.020 |
Why?
|
| Graft Survival | 1 | 1991 | 480 | 0.020 |
Why?
|
| HIV Antibodies | 1 | 1988 | 71 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2008 | 70 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2013 | 1097 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 5435 | 0.020 |
Why?
|
| Citrates | 1 | 1987 | 24 | 0.020 |
Why?
|
| Pregnancy, Ectopic | 1 | 1987 | 23 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1032 | 0.020 |
Why?
|
| Bilirubin | 1 | 2008 | 131 | 0.020 |
Why?
|
| Monocytes | 1 | 2009 | 347 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 1999 | 3168 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 1987 | 81 | 0.020 |
Why?
|
| HIV | 1 | 1988 | 187 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 814 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1987 | 144 | 0.020 |
Why?
|
| Graft Rejection | 1 | 1991 | 566 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 234 | 0.020 |
Why?
|
| Aminocaproic Acid | 1 | 2006 | 4 | 0.020 |
Why?
|
| Aprotinin | 1 | 2006 | 10 | 0.020 |
Why?
|
| Catheters, Indwelling | 1 | 1987 | 158 | 0.020 |
Why?
|
| Liver Transplantation | 2 | 1987 | 1099 | 0.020 |
Why?
|
| Arterioles | 1 | 2006 | 30 | 0.020 |
Why?
|
| Creatinine | 1 | 2008 | 417 | 0.020 |
Why?
|
| Hematinics | 1 | 2006 | 60 | 0.020 |
Why?
|
| Capillaries | 1 | 2006 | 70 | 0.020 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2006 | 47 | 0.020 |
Why?
|
| Prognosis | 1 | 2015 | 5039 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2009 | 1582 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1348 | 0.010 |
Why?
|
| Factor Xa | 1 | 2005 | 19 | 0.010 |
Why?
|
| Dextrans | 1 | 2005 | 47 | 0.010 |
Why?
|
| Peptide Fragments | 2 | 2005 | 828 | 0.010 |
Why?
|
| Pyruvate Kinase | 1 | 1984 | 11 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 7142 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1984 | 240 | 0.010 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2006 | 343 | 0.010 |
Why?
|
| Bradycardia | 1 | 1984 | 61 | 0.010 |
Why?
|
| Elective Surgical Procedures | 1 | 2004 | 170 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 2949 | 0.010 |
Why?
|
| Fetal Heart | 1 | 1984 | 136 | 0.010 |
Why?
|
| Liver Diseases | 1 | 2006 | 386 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 359 | 0.010 |
Why?
|
| Incidence | 1 | 2009 | 3385 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2006 | 494 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1989 | 1351 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 1162 | 0.010 |
Why?
|
| Thrombin Time | 2 | 1990 | 4 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2005 | 1380 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 1570 | 0.010 |
Why?
|
| Hospitalization | 1 | 2006 | 1910 | 0.010 |
Why?
|
| Neoplasms | 1 | 2011 | 2985 | 0.010 |
Why?
|
| HIV Seronegativity | 1 | 1995 | 30 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2004 | 6570 | 0.010 |
Why?
|
| Ethics, Medical | 1 | 1995 | 401 | 0.010 |
Why?
|
| Adolescent | 2 | 1988 | 20538 | 0.000 |
Why?
|
| Fibrinopeptide A | 1 | 1989 | 1 | 0.000 |
Why?
|
| Fibrinopeptide B | 1 | 1989 | 1 | 0.000 |
Why?
|
| beta-Thromboglobulin | 1 | 1989 | 4 | 0.000 |
Why?
|
| Multicenter Studies as Topic | 1 | 1989 | 313 | 0.000 |
Why?
|
| Culdoscopy | 1 | 1987 | 1 | 0.000 |
Why?
|
| Ultrasonics | 1 | 1987 | 28 | 0.000 |
Why?
|
| Hypocalcemia | 1 | 1987 | 38 | 0.000 |
Why?
|
| Femoral Artery | 1 | 1987 | 189 | 0.000 |
Why?
|
| Blood Gas Analysis | 1 | 1983 | 85 | 0.000 |
Why?
|
| Positive-Pressure Respiration | 1 | 1983 | 85 | 0.000 |
Why?
|
| Urinary Catheterization | 1 | 1983 | 87 | 0.000 |
Why?
|
| Intraoperative Care | 1 | 1983 | 120 | 0.000 |
Why?
|
| Body Temperature | 1 | 1983 | 126 | 0.000 |
Why?
|
| Laparoscopy | 1 | 1987 | 520 | 0.000 |
Why?
|
| Catheterization | 1 | 1983 | 238 | 0.000 |
Why?
|
| Liver | 1 | 1987 | 1842 | 0.000 |
Why?
|
| Texas | 1 | 1988 | 3665 | 0.000 |
Why?
|
| Cardiac Catheterization | 1 | 1983 | 663 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1988 | 8625 | 0.000 |
Why?
|
| Infant | 1 | 1988 | 13233 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1988 | 14871 | 0.000 |
Why?
|
| Child | 1 | 1988 | 25834 | 0.000 |
Why?
|